Biotechnology company producing therapy that targets and destroys senescent cells.
SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on certain rare and fast track diseases, including cancer metastasis and muscle wasting diseases, such as muscular dystrophy. Beyond these indications, senescent cells are causally implicated in a wide variety of diseases including: neurodegenerative diseases; autoimmune conditions, and infectious diseases. SIWA is currently optimizing its lead antibody, SIWA 318, and in parallel, seeking partnerships to advance SIWA 318 and other related technologies to broaden and accelerate its development pipeline.
Visit website: https://siwatherapeutics.com/
People at SIWA Therapeutics
SIWA Therapeutics News
Super summary of 3rd Annual Longevity Therapeutics Summit
Lifespan.io (LEAF) - 16-Feb-2021
More and more companies making greater and greater progress - 2021 could be an exciting yearRead more...
LMC provides background and success outlook on 14 leading senolytic companies
Longevity Marketcap - 15-Dec-2020
Comprehensive review of companies' clinical and financial state of playRead more...
Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020
In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...Read more...
LEAF interviews Lewis Gruber about targeting cancer and senescent cells
Lifespan.io (LEAF) - 11-Feb-2020
Biomarker caused by glycolysis seen in all types of cancer - exciting possibilitiesRead more...